My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 9 521 / DOI: 10.3332/ecancer.2015.521

Clinical Study

Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent

Itraconazole, a common triazole anti-fungal drug in widespread clinical use, has evidence of clinical activity that is of interest in oncology. There is evidence that at the clinically relevant doses, itraconazole has potent anti-angiogenic activity, and that it can inhibit the Hedgehog signalling pathway and may also induce autophagic growth arrest. The evidence for these anticancer effects, in vitro, in vivo, and clinical are summarised, and the putative mechanisms of their action outlined. Clinical trials have shown that patients with prostate, lung, and basal cell carcinoma have benefited from treatment with itraconazole, and there are additional reports of activity in leukaemia, ovarian, breast, and pancreatic cancers. Given the evidence presented, a case is made that itraconazole warrants further clinical investigation as an anti-cancer agent. Additionally, based on the properties summarised previously, it is proposed that itraconazole may synergise with a range of other drugs to enhance the anti-cancer effect, and some of these possible combinations are presented in the supplementary materials accompanying this paper.

Keywords: Drug repurposing, itraconazole, Hedgehog pathway inhibition, ReDO project

Loading Article Metrics ... Please wait

Related articles

Research: VERO® radiotherapy for low burden cancer: 789 patients with 957 lesions

Abstract | Full Article | PDF Published: 29 Sep 2016 / DOI: 10.3332/ecancer.2016.677

Clinical Study: Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2

Abstract | Full Article | PDF Published: 29 Sep 2016 / DOI: 10.3332/ecancer.2016.676

Conference Report: Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27–28 May, 2016, Rosario, Argentina

Abstract | Full Article | PDF | Spanish Published: 06 Sep 2016 / DOI: 10.3332/ecancer.2016.672

Review: Maps and atlases of cancer mortality: a review of a useful tool to trigger new questions

Abstract | Full Article | PDF Published: 01 Sep 2016 / DOI: 10.3332/ecancer.2016.670

Conference Report: Highlights from the 2016 WIN Symposium, 27–29 June 2016, Paris: personalised therapy beyond next-generation sequencing

Abstract | Full Article | PDF Published: 24 Aug 2016 / DOI: 10.3332/ecancer.2016.669



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence